Lumida
/KURA
⌘K
Kura Oncology Inc

Kura Oncology Inc

KURA
$11.39USD-1.56%-0.18 today

MARKET CAP

1.0B

P/E (TTM)

FWD P/E

DAY RANGE

$11 – $12

52W RANGE

$7
$14

AI Summary

Stalk
StalkMedium

KURA remains in a constructive medium- and long-term uptrend but is undergoing a short-term pullback toward the 50-day SMA. No oversold or exhaustion signals are present, so new exposure is best deferred until price accepts support at the 50-day SMA and confirms resumed upside momentum.

  • Q2 2026 revenue $20.9M (+36% YoY); KOMZIFTI sales $9.1M (+57% QoQ)
  • $519M in cash/short-term investments funds operations to 2028 Phase 3 readout
  • Q2 net loss $68.3M; trailing 12-month net loss ~$296.8M
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2024FY 2025TREND
Sales, Adj.$53.9M$67.5M
YoY %+25.2%
P / Sales13.9x13.5x
EV / Sales16.2x19.7x
Gross Profit, Adj.$53.9M$67.4M
YoY %+25.1%
Margin %100.0%99.9%
EV / Gross Profit16.2x19.7x
EBITDA, Adj.$-192.3M$-302.6M
YoY %-16.6%-57.3%
Margin %-357.0%-448.4%
EV / EBITDA-4.5x-4.4x
EBIT$-193.2M$-303.6M
YoY %-16.5%-57.2%
Margin %-358.5%-449.9%
EV / EBIT-4.5x-4.4x
Net Income$-174.0M$-278.7M
YoY %-14.0%-60.2%
Net Margin-322.9%-412.9%
EPS (GAAP)-$2.02-$3.18
YoY %+2.9%-57.4%